HUTCHMED has entered into an exclusive development and licensing agreement with GSK for HMPL-A830, an investigational antibody-targeted therapy conjugate (ATTC) designed to target KRAS and EGFR in solid tumours. EGFR is an established driver of tumour growth in several solid cancers, including colorectal, pancreatic and non-small-cell lung cancers. It also plays an important role in resistance to KRAS-targeted treatments, particularly in colorectal cancer. Targeting both EGFR and KR

As pharmaceutical manufacturers worldwide continue to navigate the implementation of PIC/S GMP Annex 1, a landmark international symposium in Japan will bring together regulators, industry leaders, researchers, and quality professionals to explore practical strategies for advancing aseptic manufacturing and contamination control. The PDA Aseptic Manufacturing and Regulatory Science Symposium 2026, jointly organized by PDA Asia Pacific and the PDA Japan Chapter, will take place on 22

Weave Bio, the leader in AI-native regulatory automation for drug development, today announced a collaboration with Takeda to deploy the Weave platform across 14 active programs in multiple global markets. The collaboration brings together Weave's AI capabilities and Takeda's regulatory expertise to support innovation in regulatory workflows. “Regulatory communications are the most knowledge-intensive workflows in all of drug development, and for too long that knowledg

Hong Kong Baptist University (HKBU) InnoHK Centre for Chinese Herbal Medicine Drug Development (CDD) co-organised the inaugural “2026 International Symposium on Innovation and R&D in Traditional Chinese Medicine” on 22 August, in partnership with Hong Kong Science and Technology Parks Corporation (HKSTP) and China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. The symposium brought together leading scholars, industry leaders, and research institution representatives i

Medical device organizations are under increasing pressure to deliver more innovation with fewer resources while navigating regulatory complexity, rising development costs, portfolio congestion, and growing demands for faster commercialization. Despite investments in Enterprise PMOs, portfolio governance, and digital PPM platforms, many organizations still struggle with strategic alignment, portfolio visibility, resource capacity planning, and cross-functional decision-making. This conference

Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), today announced a non-exclusive licensing agreement covering Monod Bio’s proprietary LuxSit de novo luciferase technology and NovoBodies. Under the terms of the agreement, SignalChem Biotech may incorporate the Monod Bio technologies into custom luminescent assay development and protein-fusion services offered to third-pa

SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its  subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, ,today announced that its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind”) has advanced with the publication in the United States of a patent application

SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its  subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, ,today announced that its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind”) has advanced with the publication in the United States of a patent application

Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, today announced the continued advancement of its AI ecosystem – a unified, enterprise approach that embeds artificial intelligence (AI) directly into the core of clinical development. By combining deep therapeutic expertise, healthcare professional intelligence and modern AI technologies, Syneos Health is helping sponsors navigate an increasingly complex development landscape.  Ground

Andelyn Biosciences, Inc., a leading patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Queen's University to develop and manufacture AAV9-GM2, a gene therapy candidate for the treatment of GM2 gangliosidoses, such as Tay-Sachs and Sandhoff diseases. GM2 gangliosidosis is a rare, inherited disorder that progressively destroys nerve cells in the brain and spinal cord. While the most common form presents in infancy,